DaxibotulinumtoxinA for Injection is currently under Biologics License Application review.
Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection.
DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
“We are excited to partner with Revance and their efforts to establish a new standard in aesthetic and therapeutic neuromodulator offerings,” says Jean-Baptiste Agnus, VP of Sales at Ajinomoto Bio-Pharma Services, in a news release. “This partnership underscores our commitment to be a leading, trusted, innovative partner to our clients and reinforces our company mission to improve the health of humankind.”
“We are delighted to be partnering with Aji Bio-Pharma for the production of our innovative product and bolstering our supply chain resiliency,” adds Brian Blagg, Vice President, Engineering & Supply Chain at Revance. “Aji Bio-Pharma’s manufacturing infrastructure, long-standing experience and customer-centric service, were important to this collaboration.”
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs.
